For the quarter ending 2026-03-31, ABT had -$1,719M decrease in cash & cash equivalents over the period. $916M in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net earnings | 1,077 | 1,776 | 1,644 | 1,779 |
| Depreciation | 381 | 370 | 371 | 357 |
| Amortization of intangible assets | 422 | 422 | 420 | 420 |
| Share-based compensation | 317 | 113 | 120 | 142 |
| Investing and financing losses, net | - | -65 | - | - |
| Trade receivables | 42 | -222 | 202 | 410 |
| Inventories | 420 | -234 | -213 | -3 |
| Prepaid expenses and other assets | - | 1,295 | - | - |
| Trade accounts payable and other liabilities | - | 954 | - | - |
| Income taxes | - | -5 | - | - |
| Other, net | -295 | - | -54 | 769 |
| Net cash from operating activities | 1,315 | 3,315 | 2,787 | 2,047 |
| Acquisitions of property and equipment | 399 | 689 | 496 | 502 |
| Acquisitions of businesses and technologies, net of cash acquired | 19,798 | 20 | 55 | 30 |
| Proceeds from business dispositions | - | 0 | 0 | 0 |
| Purchases of investment securities | - | 167 | - | - |
| Proceeds from sales of investment securities | - | 3 | - | - |
| Sales (purchases) of other investment securities, net | 302 | - | 117 | -258 |
| Other | -34 | -6 | -4 | -2 |
| Net cash from (used in) investing activities | -20,324 | -913 | -457 | -582 |
| Net borrowings (repayments) of short-term debt and other | 31 | -71 | 8 | -16 |
| Proceeds from issuance of long-term debt and debt with maturities over 3 months | - | 5 | - | - |
| Proceeds from issuance of long-term debt | 19,636 | - | 2 | 222 |
| Repayments of long-term debt and debt with maturities over 3 months | - | 1,504 | - | - |
| Repayments of long-term debt | 894 | - | 1,949 | -1,427 |
| Purchases of common shares | 180 | 302 | 305 | 6 |
| Proceeds from stock options exercised | 116 | 5 | 69 | 35 |
| Dividends paid | 1,098 | 1,030 | 1,031 | 1,029 |
| Other | - | 0 | 0 | -82 |
| Net cash from (used in) financing activities | 17,313 | -1,397 | -1,760 | -1,097 |
| Effect of exchange rate changes on cash and cash equivalents | -23 | 6 | -10 | 51 |
| Net increase (decrease) in cash and cash equivalents | -1,719 | 1,011 | 560 | 419 |
| Cash and cash equivalents, beginning of year | 8,522 | 7,511 | 6,951 | 6,532 |
| Cash and cash equivalents, end of period | 6,803 | 8,522 | 7,511 | 6,951 |
ABBOTT LABORATORIES (ABT)
ABBOTT LABORATORIES (ABT)